376 related articles for article (PubMed ID: 27140876)
21. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Yu HY; Lee CY; Lin LG; Chao Y; Li CP
J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
[TBL] [Abstract][Full Text] [Related]
22. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Frampton JE
Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
[TBL] [Abstract][Full Text] [Related]
23. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Chun JW; Woo SM; Lee SH; Choi JH; Park N; Kim JS; Cho IR; Paik WH; Lee WJ; Ryu JK; Kim YT
Ther Adv Med Oncol; 2022; 14():17588359221119539. PubMed ID: 36062047
[TBL] [Abstract][Full Text] [Related]
24. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Takada R; Ikezawa K; Yamai T; Watsuji K; Seiki Y; Kawamoto Y; Hirao T; Higashi S; Urabe M; Kai Y; Nakabori T; Uehara H; Kotani M; Yagi T; Kimura M; Nozaki K; Takagi M; Ohkawa K
BMC Cancer; 2023 Jul; 23(1):711. PubMed ID: 37518012
[TBL] [Abstract][Full Text] [Related]
25. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
[TBL] [Abstract][Full Text] [Related]
26. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
Nagashima S; Kobayashi S; Tsunoda S; Yamachika Y; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
Int J Clin Oncol; 2024 Feb; 29(2):188-194. PubMed ID: 37991558
[TBL] [Abstract][Full Text] [Related]
27. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
[TBL] [Abstract][Full Text] [Related]
28. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
29. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C; Frontado Graffe FJ; Bartels A; Sadeghlar F; Zhou T; Mahn R; Marinova M; Feldmann G; Brossart P; Glowka TR; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Gastrointest Oncol; 2023 Feb; 14(1):352-365. PubMed ID: 36915455
[TBL] [Abstract][Full Text] [Related]
30. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
[TBL] [Abstract][Full Text] [Related]
31. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
32. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
34. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Ueno M
Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174
[TBL] [Abstract][Full Text] [Related]
35. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
[TBL] [Abstract][Full Text] [Related]
36. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
Woo W; Carey ET; Choi M
Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.
Bang K; Cheon J; Jeong JH; Im HS; Kim KP; Ryoo BY; Yoo C
Ther Adv Med Oncol; 2021; 13():17588359211003053. PubMed ID: 33796153
[TBL] [Abstract][Full Text] [Related]
38. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Chiu TJ; Yang SH; Chiu SC; Hsueh SW; Chiang NJ; Li CP; Bai LY; Cheng FM; Chuang SC; Shan YS; Chan DC; Chen LT; Yen CJ; Peng CM; Su YY; Chen YY; Chen JS; Chou WC
J Hepatobiliary Pancreat Sci; 2022 Jun; 29(6):670-681. PubMed ID: 35182031
[TBL] [Abstract][Full Text] [Related]
39. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.
Verbruggen L; Verheggen L; Vanhoutte G; Loly C; Lybaert W; Borbath I; Vergauwe P; Hendrickx K; Debeuckelaere C; de Haar-Holleman A; Van Laethem JL; Peeters M
Ther Adv Med Oncol; 2023; 15():17588359231181500. PubMed ID: 37600936
[TBL] [Abstract][Full Text] [Related]
40. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
